Overview

Effect of Dehydroepiandrosterone (DHEA) on Hot Flashes in Postmenopausal Women

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of the study is to evaluate the effect of daily oral intake of DHEA 50 mg for 4 months on reducing vasomotor symptoms (hot flashes) compared to placebo administration in postmenopausal women.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Centre Hospitalier Universitaire de Québec, CHU de Québec
CHU de Quebec-Universite Laval
Treatments:
Dehydroepiandrosterone
Criteria
Inclusion Criteria:

- Healthy postmenopausal women with 50 or more moderate to severe hot flushes.

- Women between 40 to 70 years of age.

Exclusion Criteria:

- Body mass index (BMI) of 35 kg/m2 or more.

- Significant metabolic and endocrine diseases.

- Diagnosis of cancer.

- Use of steroids or drugs that interfere with the metabolism of estrogen.

- Use of any systemic estrogen, progestin, or DHEA in the eight weeks prior to
randomization.

- Use of alternative therapies or natural products to treat postmenopausal symptoms in
the four weeks prior to randomization.

- Palpable fibroids or uterine prolapse: Grade 2 or 3.

- Cigarette smoking